| I-75 Michael Monine Prediction and validation of antisense oligonucleotide distribution in human central nervous system Wednesday 10:00-11:30 |
| I-76 Nele Mueller-Plock Population pharmacokinetic - pharmacodynamic analysis of dopamine D2 receptor occupancy following doses of TV 46000, an extended release suspension of risperidone for treatment of schizophrenia Wednesday 10:00-11:30 |
| I-77 Paraskevi Papakyriakopoulou Donepezil brain and blood pharmacokinetic modeling after nasal film and oral solution administration in mice Wednesday 10:00-11:30 |
| I-78 Juan Jose Perez Ruixo Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis Wednesday 10:00-11:30 |
| II-86 Elena Righetti A mechanistic model of α-synuclein aggregation and degradation to bridge in vitro and in vivo research on Parkinson’s disease. Wednesday 15:35-17:00 |
| II-88 Rajendra Singh A Time-to-event Modeling Approach Supporting the Safety Profile of New Deutetrabenazine (AUSTEDO) Titration Schemes in Patients with Tardive Dyskinesia and Huntington’s Disease Wednesday 15:35-17:00 |
| II-90 Sara Soufsaf An Exploratory Analysis of the Performance of Methylphenidate Regimens Based on a PKPD Model of Dopamine and Norepinephrine Transporter Occupancy Wednesday 15:35-17:00 |
| II-97 Yanlin Wang Development of a Population Pharmacokinetic Model to Describe the Pharmacokinetics of Aripiprazole 2-Month Ready-to-Use, a Novel Long-Acting Injectable Formulation of Aripiprazole for Administration Once Every 2 Months Wednesday 15:35-17:00 |
| IV-02 Enrique José Bandín Vilar Population pharmacokinetics of aripiprazole and its active metabolite dehydroaripiprazole in subjects receiving once-monthly intramuscular aripiprazole. Thursday 15:25-16:55 |
| IV-03 Bruna Bernar Dias PK/PD modelling of the effect of nanoencapsulated quetiapine on cortical dopamine concentrations in schizophrenia phenotyped rats Thursday 15:25-16:55 |
| IV-04 Divakar Budda Mu-opioid receptor binding of morphine and its main metabolites: impact of non-linear BBB transport of morphine. Thursday 15:25-16:55 |
| IV-05 Chao Chen Model-based meta-analysis of aggregate data on Parkinson’s disease clinical scores to inform future trial design Thursday 15:25-16:55 |
| IV-08 Emma Eckernäs Optimizing infusion rates for N,N-dimethyltryptamine based on either a continuous variable model or a bounded integer model Thursday 15:25-16:55 |
| IV-14 Farina Hellmann Population pharmacokinetic modeling of total active moiety exposure following doses of TV 46000, a long-acting subcutaneous risperidone injection Thursday 15:25-16:55 |
| IV-15 Niels Hendrickx Predicting individual disease progression including parameter uncertainty in rare neurodegenerative diseases: the example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS) Thursday 15:25-16:55 |
